topic

Correction: Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS
Journal for ImmunoTherapy of Cancer Dec 2023, 11 (12) e007790corr1; DOI: 10.1136/jitc-2023-007790corr1
442-L Development of Panck T cells, MR1-restricted pan-cancer-killing CD8⁺ T cells, as an adoptive T cell therapeutics
Sunhee Hwang, Young H Kim, Yeeun Bak, Byoung S Kwon

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1796; DOI: 10.1136/jitc-2023-SITC2023.0442-L
442-O Identifying cancer-specific T cells for immunotherapy through engineered proteins
Rongyu Zhang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1799; DOI: 10.1136/jitc-2023-SITC2023.0442-O
782-G The correlation of tumor immune microenvironment with response to neoadjuvant chemotherapy response in undifferentiated pleiomorphic sarcomas: an analysis of the NEOSARCOMICS study
Julien Vibert, Jean-Philippe Guégan, Lucile Vanhersecke, Jean-Michel Coindre, Maud Toulmonde, Mariella Spalato-Ceruso, Florent Peyraud, Alban Bessede, Antoine Italiano

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1817; DOI: 10.1136/jitc-2023-SITC2023.0782-G
782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial update
Adnan Khattak, Paolo A Ascierto, Paola Queirolo, Michael Chisamore, Daniela Kleine-Kohlbrecher, Nadia Viborg, Mads Lausen, Stine F Thorsen, Thomas Trolle, Anders Jespersen, Georgina V Long

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1818; DOI: 10.1136/jitc-2023-SITC2023.0782-H
782-I Phase I dose escalation of SAR445710, a PDL1-IL15 targeted cytokine in metastatic and/or advanced solid tumors
Jason Luke, Anthony J Olszanski, Lee Rosen, Ahmad A Tarhini, Adyb Baakili, Timothy Wagenaar, Chen Zhu, Helene Guillemin-Paveau, Meijing Wu, Raymond Perez, Giovanni Abbadessa, Christos Fountzilas

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1819; DOI: 10.1136/jitc-2023-SITC2023.0782-I
897-B A DNAJB1-PRKACA fusion peptide vaccine combined with ipilimumab and nivolumab elicits polyclonal fusion-specific T cell responses in fibrolamellar carcinoma
Allison M Kirk, Jeremy C Crawford, Zeal Kamdar, Marina Baretti, Mark Yarchoan, Paul G Thomas

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1820; DOI: 10.1136/jitc-2023-SITC2023.0897-B
897-C TROCEPT tumor-specific targeting and replication enables in-tumor production of immune checkpoint inhibitors following intravenous delivery
Rahul C Khanolkar, James A Davies, Alexander T Baker, Thomas A Webb, Alicia Teijeira-Crespo, Hanni K Uusi-Kerttula, Lucy M Williams, Samantha L Moore, Johanne M Pentier, Bent K Jakobsen, Alan L Parker, David K Cole, Andrew B Gerry, David Krige

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1821; DOI: 10.1136/jitc-2023-SITC2023.0897-C
897-D Combinational treatment of reovirus and NK cells against bladder cancer cells using an intravesical therapy mimicking in vitro assay
Yuree Lim, Jeehun Park, Joung Eun Lim, Minji Park, Seung Kwon Koh, Mijeong Lee, Sang-ki Kim, Seung-Hwan Lee, Ki-Hoon Song, Dong Guk Park, Byong Chang Jeong, Duck Cho

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1822; DOI: 10.1136/jitc-2023-SITC2023.0897-D
897-E STING-activating nanosystem for synergistic immuno-sonodynamic therapy of pancreatic cancer
Kai Xiao

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1823; DOI: 10.1136/jitc-2023-SITC2023.0897-E

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages